Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 11.1% – What’s Next?

Ascendis Pharma A/S (NASDAQ:ASND)’s stock price was down 11.1% during trading on Tuesday . The stock traded as low as $234.12 and last traded at $235.6050. 288,955 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 667,871 shares. The stock had previously closed at $264.92.

Trending Headlines about Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: The company authorized a share repurchase program of up to $400 million, signaling management’s confidence in the stock’s value and providing potential support for per-share results. Ascendis Pharma board approves $400M share repurchase program
• Positive Sentiment: Ascendis will regain rights to TransCon technology programs in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide. Full ownership could allow the company to capture more of the program’s future economics and set its own development strategy. Ascendis Pharma Regains Rights to Obesity Drug
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, management discussed Ascendis’ pipeline and business strategy. The presentation gave investors additional context as they assess the company’s transition to operating independently. Morgan Stanley Healthcare Conference Transcript
• Neutral Sentiment: Recent commentary characterizes Ascendis as returning to “full independence,” with investors weighing greater control over its technology against the loss of a major commercial partner. Ascendis Pharma: Back To Full Independence
• Negative Sentiment: The Novo collaboration’s termination removes partner support for development and commercialization, while Ascendis assumes more responsibility for advancing its obesity and type 2 diabetes programs. Investors initially viewed that uncertainty negatively, and Raymond James downgraded the shares to Outperform from a more bullish stance. Ascendis Pharma Stock Falls Over Share Repurchase Authorization

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ASND shares. Stifel Nicolaus lowered their price target on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a report on Monday, August 31st. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Barclays reduced their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Finally, HC Wainwright set a $344.00 target price on Ascendis Pharma A/S in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $310.75.

Ascendis Pharma A/S Stock Performance

The stock has a 50 day moving average of $256.23 and a 200 day moving average of $242.60. The company has a market capitalization of $15.45 billion, a price-to-earnings ratio of 19.22 and a beta of 0.35. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. As a group, analysts predict that Ascendis Pharma A/S will post 3.69 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were acquired at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company’s stock, valued at $714,357. The trade was a 222.22% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in ASND. Personal CFO Solutions LLC raised its stake in shares of Ascendis Pharma A/S by 4.4% during the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 64 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the period. Main Management ETF Advisors LLC boosted its stake in Ascendis Pharma A/S by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the biotechnology company’s stock worth $2,338,000 after purchasing an additional 112 shares during the period. Allworth Financial LP grew its holdings in Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 122 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its holdings in Ascendis Pharma A/S by 0.6% during the 4th quarter. Kennedy Capital Management LLC now owns 19,862 shares of the biotechnology company’s stock valued at $4,235,000 after buying an additional 123 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.